Antibody against Interferon-α 2b in Serum of the Patients with Chronic Hepatitis C and its Clinical Significance: A Clinical Trial

Abstract

suppresses HCV replication are not well-known; only limited benefits are achieved with the therapy because the virus in turn, directs some mechanisms to resist the host IFN-α response. The present study was undertaken to determine the therapeutic effects of IFN-α 2b and to measure the serum level of antibody against IFN-α 2b (anti-IFN-α 2b) after treatment with IFN-α 2b in patients with chronic hepatitis C.